Immunovia AB (OSTO:IMMNOV) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
43 GF Score
Price kr0.20
GF Value kr0.07
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:IMMNOV vs TMO, DHR, IDXX: Short Interest Comparison

For the Diagnostics & Research subindustry, Immunovia AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovia AB Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Short Interest falls into.


OSTO:IMMNOV
43GF Score
Immunovia AB OSTO:IMMNOV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.20 is trading 182.3% above its estimated GF Value™ of kr0.07. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Short Interest:
  • GF Value™: kr0.07 vs. price of kr0.20 (182.3% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for OSTO:IMMNOV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.20
Price
kr0.07
GF Value